Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Other Accumulated Expenses (2016 - 2024)

Historic Other Accumulated Expenses for Iovance Biotherapeutics (IOVA) over the last 8 years, with Q1 2024 value amounting to $4.0 million.

  • Iovance Biotherapeutics' Other Accumulated Expenses fell 724.94% to $4.0 million in Q1 2024 from the same period last year, while for Mar 2024 it was $4.0 million, marking a year-over-year decrease of 724.94%. This contributed to the annual value of $6.6 million for FY2023, which is N/A changed from last year.
  • According to the latest figures from Q1 2024, Iovance Biotherapeutics' Other Accumulated Expenses is $4.0 million, which was down 724.94% from $6.6 million recorded in Q4 2023.
  • In the past 5 years, Iovance Biotherapeutics' Other Accumulated Expenses registered a high of $6.6 million during Q4 2023, and its lowest value of $4.0 million during Q1 2024.